Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ENDURANCE: Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Dutch Daily Clinical Practice. Part B1

NCT07663786 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT07663786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07663786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ENDURANCE: Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Dutch Daily Clinical Practice. Part B1
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Active, not recruiting
Start date
October 9, 2025
Completion date
February 1, 2027
Enrollment
726 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal adenocarcinoma, gastric adenocarcinoma, gastro-esophageal junction adenocarcinoma